He might have a dirty, kind of disheveled rabbit to pull out.
I've had many discussions about having a buyout for a "bad" price for many investors, but which would get Denner and other funds that entered relatively recently an acceptable exit point. It's not a glorious $20 buyout, or even a "I'll grumble and take it" $10 buyout, but something more in the $5-7 range that he profits somewhat on and allows him to GTFO without taking a big blackeye.
Obviously that hinges on him having, or getting, the leverage to accomplish that, which is obviously a wildcard.
One thing about a "bad" buyout still being plausible is that Vascepa has a gigantic profit margin when you compare product cost vs selling price. Amarin needs this massive profit margin to keep the lights on, but a BP doesn't, they can make it up in volume and massively reduced running costs. If Pfizer is selling Vascepa, the costs of Pfizer's CEO, their electrical bills, their reps, their IR department and so on are all spread over Pfizer's profits from their massive portfolio while with Amarin, all those costs depend solely on Vascepa profits. The cost of a $2 Billion buyout could be recouped relatively quickly by a BP while $2 billion in net profits for Amarin may never actually happen.
Market Data 
Markets 
AI
